Characteristics of the target population of biological disease-modifying antirheumatic drug-naïve patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis based on the ixekizumab SPIRIT-P1 and -P2 clinical trials
| Parameter | Mean value |
| Age (years) | 51.0 |
| Proportion male (%) | 51.8 |
| Proportion female (%) | 48.2 |
| Body weight (kg) | 87.0 |
| Baseline HAQ-DI score | 1.19 |
| Baseline PASI score | 20.4 |
Patient characteristics based on pooled data from the intent-to-treat trial populations of SPIRIT-P1 and SPIRIT-P2 with ixekizumab.15 16
HAQ-DI, Health Assessment Questionnaire‒Disability Index; PASI, Psoriasis Area Severity Index.